A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
NCT05120297
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
452
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis Vulgaris
Interventions
DRUG:
AK101
DRUG:
Placebo
Sponsor
Akeso